Darbepoetin Alfa vs BYM338
Head-to-head comparison of Darbepoetin Alfa (Darbepoetin alfa, recombinant human erythropoiesis-stimulating protein) and BYM338 (Bimagrumab (BYM338)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Darbepoetin Alfa | BYM338 |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Darbepoetin alfa, recombinant human erythropoiesis-stimulating protein | Bimagrumab (BYM338) |
| Molecular Weight | ≈37,000 Da | ~148 kDa |
| Half-Life | ~21 h IV; ~49 h SC | ~2-3 weeks |
| Amino Acids | 165 | N/A |
| Typical Dose | 0.45 mcg/kg weekly SC or 0.75 mcg/kg every 2 weeks | 10-30 mg/kg IV in trials |
| Route | Subcutaneous/IV | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 210 | 140 |
| Research Status | Clinical | Clinical |
Darbepoetin Alfa Benefits
- ✓longer-acting erythropoiesis
- ✓stable hemoglobin
- ✓increased oxygen delivery
- ✓may improve aerobic capacity
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
Darbepoetin Alfa Dosing
0.45 mcg/kg weekly SC|0.75 mcg/kg every 2 weeks SC|Dose-adjust to hemoglobin response
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
Darbepoetin Alfa Side Effects
- ⚠hypertension
- ⚠thromboembolism
- ⚠headache
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Research Overview
Darbepoetin Alfa
Clinical studies show durable hemoglobin correction with less frequent dosing than epoetin alfa. The endurance benefit, where present, would come from improved oxygen-carrying capacity rather than a direct ergogenic pathway.
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.